Užas u Srbiji: Rusi u Srbiji proizvode cjepivo protiv korone

Production of Sputnik V launched in Serbia

Moscow, April 14, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Institute of Virology, Vaccines and Sera “Torlak” announce the launch of production of the Russian Sputnik V vaccine against coronavirus in Serbia.

Serbia has become the first country in Southern Europe to produce Sputnik V. Production of Sputnik V in Serbia meets the best vaccine manufacturing standards.

The vaccine could be exported to other countries of the region at a later stage. Vaccination against coronavirus with the Russian vaccine started in Serbia on January 6, 2021.

To date Sputnik V has been registered in 60 countries globally with total population of 3 billion people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Production of Sputnik V vaccine was successfully launched in Serbia in a short time frame as part of the agreements between RDIF and the Torlak Institute. Serbia became the first European country to start producing the Russian vaccine. Since the beginning of the year, Sputnik V has been actively used to vaccinate the population of the country, and the scale of vaccination may be significantly increased thanks to the launch of local production.”

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB2 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru

https://rdif.ru/Eng_fullNews/6710/

-------------------------------------------

Koje budale. Sad ih nikad neće primiti u Europsku Uniju.

Index Vijesti/Hina
9.4.2021.

RUSKA farmaceutska tvrtka R-Pharm trebala bi u svom pogonu u Bavarskoj svaki mjesec proizvoditi do 10 milijuna doza cjepiva Sputnik V, kazao je danas njezin direktor Aleksej Repik.

https://www.index.hr/vijesti/clanak/ruska-firma-planira-proizvodnju-sputnika-v-u-njemackoj/2267605.aspx

Speare Shaker wrote:Index Vijesti/Hina
9.4.2021.

RUSKA farmaceutska tvrtka R-Pharm trebala bi u svom pogonu u Bavarskoj svaki mjesec proizvoditi do 10 milijuna doza cjepiva Sputnik V, kazao je danas njezin direktor Aleksej Repik.

https://www.index.hr/vijesti/clanak/ruska-firma-planira-proizvodnju-sputnika-v-u-njemackoj/2267605.aspx

"... no konačna odluka će ovisiti o tome hoće li Sputnik V dobiti zeleno svjetlo Europske agencije za lijekove (EMA)."

crvenkasti wrote:

Speare Shaker wrote:Index Vijesti/Hina
9.4.2021.

RUSKA farmaceutska tvrtka R-Pharm trebala bi u svom pogonu u Bavarskoj svaki mjesec proizvoditi do 10 milijuna doza cjepiva Sputnik V, kazao je danas njezin direktor Aleksej Repik.

https://www.index.hr/vijesti/clanak/ruska-firma-planira-proizvodnju-sputnika-v-u-njemackoj/2267605.aspx

"... no konačna odluka će ovisiti o tome hoće li Sputnik V dobiti zeleno svjetlo Europske agencije za lijekove (EMA)."

To slijedi u svibnju. Po sadašnjim najavama.

Speare Shaker wrote:Index Vijesti/Hina
9.4.2021.

RUSKA farmaceutska tvrtka R-Pharm trebala bi u svom pogonu u Bavarskoj svaki mjesec proizvoditi do 10 milijuna doza cjepiva Sputnik V, kazao je danas njezin direktor Aleksej Repik.

Zanimljivo, isti su kupili od Pfizera.

Speare Shaker wrote:

crvenkasti wrote:

Speare Shaker wrote:Index Vijesti/Hina
9.4.2021.

RUSKA farmaceutska tvrtka R-Pharm trebala bi u svom pogonu u Bavarskoj svaki mjesec proizvoditi do 10 milijuna doza cjepiva Sputnik V, kazao je danas njezin direktor Aleksej Repik.

https://www.index.hr/vijesti/clanak/ruska-firma-planira-proizvodnju-sputnika-v-u-njemackoj/2267605.aspx

"... no konačna odluka će ovisiti o tome hoće li Sputnik V dobiti zeleno svjetlo Europske agencije za lijekove (EMA)."

To slijedi u svibnju. Po sadašnjim najavama.

Bumo vidli.
Odobrenje Sputnika V izbija iz ruku zapadnih proizvođača cjepiva ogromnu lovu.
Isto kao što Sjeverni tok izbija lovu iz ruku zapadnih dobavljača plina.

Kapital vlada, a ne razum.

Sputnik V za region ide kroz BG

Ovo u Njemačkoj bit će za zemlje EU.